Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment
for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can
significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2
therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea
in breast cancer patients.